Search for Clinical Trials
Your Search for state of North Carolina Identified 15 Trial(s):
Purpose: To evaluate the effects of AC-1204 on cognition, activities of daily living, quality of life, pharmacokinetic measures, and safety in people with mild to moderate Alzheimer's disease.
Purpose: To examine whether the potential benefits of low-dose aspirin outweigh the risks in people over age 70.
Purpose: To evaluate the safety, tolerability, and efficacy of AVP-923 (dxtromethorphan/qinidine) for the treatment of agitation in people with Alzheimer's disease.
Purpose: To define a biomarker using proteins found in cerebrospinal fluid to distinguish people with mild to moderate Alzheimer's disease from healthy, elderly people.
Purpose: To standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden.
Purpose: To evaluate the performance of the COGNISION™ system as a tool to assist physicians in diagnosing Alzheimer's disease in real-world clinical settings.
Purpose: To determine the response of older adults with both depression and cognitive impairment to donepezil vs. placebo after treatment with antidepressants. The goal is improve cognition and delay conversion to dementia.
Purpose: To determine whether ELND005 is effective in treating symptoms of agitation and aggression in people with Alzheimer's disease.
Purpose: To evaluate the safety and efficacy of the experimental drug gantenerumab on cognition and functioning in people with prodromal (very early stage) Alzheimer's disease.
Purpose: To examine whether decision support for goals of care can improve the quality of communication, decision-making, and palliative care for nursing home residents with advanced dementia.
Purpose: To determine whether positron emission tomography (PET) scanning can help distinguish patients with early Alzheimer's changes in their brains from those having other causes of cognitive impairment more accurately than current clinical practices.
Purpose: To assess the efficacy and safety of MK-8931 as a possible treatment for Alzheimer's disease.
Purpose: To assess the safety and tolerability of RG1662 in individuals with Down syndrome.
Purpose: To evaluate the efficacy and safety of RO4602522 in people with moderate-stage Alzheimer disease who take donepezil or rivastigmine.
Purpose: To determine whether intensive blood pressure lowering will reduce the incidence of all-cause dementia, reduce the decline of global cognitive function in key specific domains, and show changes in brain structure.
